Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors.
Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors.
复制标题
曲甲喹诺类似物对人β(1)-和β(3)-肾上腺素能受体的生化活性。
DOI：
10.1159/000056071
复制
发表时间：
2001
期刊：
影响因子：
3.1
通讯作者：
Feller,DR
中科院分区：
文献类型：
--
作者：
Konkar,AA;Nikulin,VI;DeLosAngeles,J;Hong,SS;Fertel,RH;Miller,DD;Feller,DR
The biochemical activities of trimetoquinol (TMQ) analogs were evaluated at the human β1- and β3-adrenergic receptor (AR) subtypes expressed in Chinese hamster ovary cells. In radioligand binding assays, the 1-benzyl iodine-substituted analogs exhibited higher binding affinities at both β1- and β3-AR subtype as compared to TMQ. In cAMP accumulation assays, these analogs exhibited high potencies at both β1- and β3-AR. The 3′,5′-diiodo-4′-amino analog of TMQ was the most potent β3-AR agonist, 17-fold more potent at the β3-AR versus the β1-AR. Masking of the 6,7-dihydroxy group of the catechol ring of 3′,5′-diiodo-4′-acetamido analog of TMQ, a potent β1- and β3-AR agonist, abolished activity at both β-AR subtypes. Furthermore, substitution of a strong electron withdrawing group such as the trifluoromethyl moiety at the 1-benzyl ring of TMQ dramatically decreased potency at β1- and β3-AR compared to TMQ. Replacement of the 1-benzyl ring of TMQ with a naphthalene ring did not alter affinity but reduced potency of resulting 1-naphthylmethyl and 2-naphthylmethyl analogs at β1- and β3-AR compared to TMQ. Our results define the structural and electronic properties of substituents on TMQ necessary for potent activation of β1- and β3-AR and suggest that further modifications of the 1-benzyl iodine-substituted analogs may yield potent β3-AR agonists.
